HIGHLIGHTS
- who: Parviz Owlia and Nader Bagheri from the Sichuan University, China have published the article: COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy, in the Journal: (JOURNAL)
- what: The study showed that healthy individuals treated with baricitinib had varying degrees of inhibition of cytokine-dependent phosphorylated STAT (pSTAT). Inhibitors that target SARS-CoV2 proteases, the 3CLPRO and PLPRO, which are responsible for SARS-CoV-2 duplication and spread, are evaluated in the study by Jade et_al FDA-approved medications in the Zinc database, COVID-19 chemicals in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.